Adamas Pharma (ADMS): Reiterating Buy Ahead Of World Parkinson Congress - Mizuho

September 22, 2016 9:04 AM EDT
Get Alerts ADMS Hot Sheet
Price: $16.17 -1.52%

Rating Summary:
    9 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade ADMS Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Mizuho Securities analyst, Irina Koffler, reiterated her Buy rating on shares of Adamas Pharmaceuticals (NASDAQ: ADMS) ahead of the company's presentation at the World Parkinson Congress this week. The company will be presenting:

1) The full results of its Phase III EASE-LID 3 study that demonstrated a 1.9 hour improvement in ON time without troublesome dyskinesia, and a 1.1 hour decrease in OFF time, collectively providing the patient with 3 hours of symptom relief per day

2) A post-hoc analysis of the Phase III EASE-LID trial that demonstrated directionally positive improvements in all 10 activities of daily living (ADL).

At the end of 12 weeks, patients that received ADS-5102 demonstrated the most positive directional improvements in scores for public and social settings, walking and balance, exciting or emotional settings, and eating tasks. Approximately 46-72% of patients reported impairment on these activities at baseline.

The analyst is encouraged by the improvement in the walking and balance score which may be a positive read-through for the company's second ADS-5102 program in MS Gait. No change to the price target of $26.

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $17.81 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Irina Koffler

Add Your Comment